Key result
The converting enzyme inhibitor SQ 20881 reduced the vasoconstrictor effect of angiotensin I by up to 87% in the isolated rat kidney, indicating a low rate of intrarenal conversion.
The converting enzyme inhibitor SQ 20881 effectively blocks the vasoconstrictor effect of angiotensin I in the isolated rat kidney, highlighting the dynamics of intrarenal angiotensin conversion.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for ACE inhibition; leaves open intrarenal conversion dynamics in intact models.
In the isolated rat kidney, perfused at constant pressure with a medium free from renin substrate, addition of angiotensin I to the perfusate decreases renal ‘plasma’ flow. 2. A peptide inhibitor, SQ 20881, of converting enzyme reduces the vasoconstrictor effect of angiotensin I up to a maximum of 87%, the degree of inhibition being dose-dependent. 3. The molar, ratio of equi-effective doses of angiotensin I and angiotensin II was 50:1, indicating a low rate of intrarenal conversion of the decapeptide. 4. The vasoconstrictor effect elicited by the addition of renin substrate to the perfusate was not inhibited by SQ 20881, even if the concentration was fifteen times that which produced the maximum inhibition of conversion of angiotensin I.
No takes yet. Share an insight, caveat, or question.
Hofbauer et al. (1973) studied this question. SQ 20881 (converting enzyme inhibitor) was evaluated on Vasoconstrictor effect (renal plasma flow). The converting enzyme inhibitor SQ 20881 reduced the vasoconstrictor effect of angiotensin I by up to 87% in the isolated rat kidney, indicating a low rate of intrarenal conversion.
Synapse has enriched 10 related papers. Consider them for comparative context: